Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Recombinant Shingles Vaccine (CHO Cells) in Adults 40 Years and Older
ChiCTR2600128383Phase 2Recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of recombinant herpes zoster vaccine (CHO cells) in herpes zoster (HZ) (6 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Geometric mean concentration of glycoprotein E antibody, Geometric growth factor of glycoprotein E antibody and 6 more. Started Jul 2026; status: recruiting.
02
Drugs
recombinant herpes zoster vaccine (CHO cells)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on ChiCTR2600128383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128383.